Gene Therapy Being Assessed for Treatment of X-Linked Severe Combined Immunodeficiency
source: pixabay.com

Gene Therapy Being Assessed for Treatment of X-Linked Severe Combined Immunodeficiency

  Mustang Bio, a biopharmaceutical company, has been working with St. Jude Children's Research Hospital to develop MB-107, a lentiviral gene therapy to treat X-linked severe combined immunodeficiency. Mustang Bio…

Continue Reading Gene Therapy Being Assessed for Treatment of X-Linked Severe Combined Immunodeficiency

Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation

  A drug created by Agios Pharmaceuticals, TIBSOVO, was recently granted the Breakthrough Therapy designation by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (MDS) with an…

Continue Reading Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation
FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
kalhh / Pixabay

FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

Dicerna Pharmaceuticals works in ribonucleic interference (RNAi) therapies as treatments of rare diseases. They have recently been granted the orphan drug designation by the European Commission for their drug, DCR-A1AT.…

Continue Reading FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
source: pixabay.com

Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval

According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved the drug golodirsen (marketed as Vyondys 53) as a treatment for Duchenne muscular dystrophy…

Continue Reading Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
source: pixabay.com

Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

According to a story from prnewswire.com, the biopharmaceutical company InMed Pharmaceuticals, Inc. has recently announced that that company's Clinical Trial Application has been approved in the Netherlands. This approval will…

Continue Reading Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial
source: pixabay.com

With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial

According to a story from Benzinga, the drug company Abeona Therapeutics, Inc. has recently announced plans to move forward with its phase 3 clinical trial following the lifting of the…

Continue Reading With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial
Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives
source: pixabay.com

Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives

According to a story from 10tv.com, Kellan Shatto is an eight year old boy who really likes to play with Legos. He also has a rare disease: neurofibromatosis. The disease…

Continue Reading Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives